Boston Scientific drops plans to sell pain unit

Bloomberg has reported that Boston Scientific has abandoned its plans to auction off its neuromodulation business, which it had hoped to sell for up to $2 billion. Sources say companies interested in a deal were looking to pay $1 billion to $1.5 billion for the pain treatment division--much less that Boston Sci was asking. Article